rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Olivia C. Ware

Director

Company insider

Files Form 4 as: Director, Contineum Therapeutics; Director, Arcellx; Director, Revance Therapeutics; Chief Commercial Officer, Cytrx.

Every Form 4 they filed

In numbers

Trades disclosed
39
Buys
0
Sells
2
Bought
$0
Sold
$1.2M
Companies
4
Companies where not an officer
3
First trade
11 Jan 2016
Last trade
26 Jun 2026
Last filed
26 Jun 2026

Companies traded

Where they are an officer
CytrxOfficer · last 11 Jan 20160 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
CTNM Contineum TherapeuticsDirector · Biotechnology · last 26 Jun 20260 buys · 0 sells
ArcellxDirector · Biotechnology · last 28 Apr 20260 buys · 2 sells
Revance TherapeuticsDirector · last 6 Feb 20250 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
26 Jun 2026filed 26 Jun 2026CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,000 at $0.00filing
26 Jun 2026filed 26 Jun 2026CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,000 at $0.00filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—36,806filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—11,459filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—8,011filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—36,806filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—11,459filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—8,011filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—9,174filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—9,174filing
26 Jun 2025filed 26 Jun 2025CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—14,750 at $0.00filing
29 May 2025filed 30 May 2025Arcellxoption or derivativeSEC FORM 4 Code A—9,174 at $0.00filing
6 Feb 2025filed 6 Feb 2025Revance TherapeuticsSEC FORM 4 Code D—15,000filing
4 Feb 2025filed 6 Feb 2025Revance TherapeuticsSEC FORM 4 Code U$61K16,675 at $3.65filing
28 May 2024filed 6 Jun 2024Arcellxoption or derivativeSEC FORM 4 Code A—8,011 at $0.00filing
24 May 2024filed 29 May 2024CTNM Contineum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,700 at $0.00filing
1 May 2024filed 3 May 2024Revance Therapeuticsoption or derivativeSEC FORM 4 Code A—23,458 at $0.00filing
1 May 2024filed 3 May 2024Revance TherapeuticsSEC FORM 4 Code A—15,000 at $0.00filing
16 Apr 2024filed 18 Apr 2024Arcellxoption or derivativeSEC FORM 4 Code M—9,402 at $0.00filing
16 Apr 2024filed 18 Apr 2024ArcellxSEC FORM 4 Code M$72K9,402 at $7.61filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed2

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.